FDA and the Federal Trade Commission (FTC) issued a warning letter to Flu and Cold Defense LLC (Boca Raton, Fla.) for making misleading, unproven claims about its GermBullet inhaler, and said the company has been marketing an untested inhaled formula as a flu remedy in violation of drug safety regulations.
FDA and the Federal Trade Commission (FTC) issued a warning letter to Flu and Cold Defense LLC (Boca Raton, Fla.) for making misleading, unproven claims about its GermBullet inhaler, and said the company has been marketing an untested inhaled formula as a flu remedy in violation of drug safety regulations.
“The recent letter that was released by FDA and the FTC about the unproven claims of the product GermBullet released by Flu and Cold Defense LLC comes at particularly sensitive time when the flu season begin sooner than expected, and this has made consumers susceptible to false claims of products that can prevent or treat the flu,” said Formulary Advisor Abimbola Farinde, PharmD, MS, clinical staff pharmacist at Clear Lake Regional Medical Center, in Webster, Texas. “Healthcare providers should strive to educate their patients on the facts and myths that currently exist about the flu. Patients should be informed that there is currently no cure or treatment for the flu, and only products that have been approved by FDA to treat the signs and symptoms of the flu are on the market. In order for any product to be considered safe and effective for the American public, it must be undergo a strict and sometimes extensive evaluation process before it is approved for release by FDA.”
According to the Associated Press, FDA regulators say they are seeing a rise in bogus flu remedies.
Flu and Cold Defense advertises GermBullet as containing “a scientifically proven, proprietary Inhalation blend of 11 essential oils. Users inhale it before, during and after exposure to coat the nasal passages for 2 to 3 hours. The organic blend is safe and does not contain synthetics, pesticides, preservatives, alcohol or zinc. The protective GermBullet Inhalation Formula is available as a liquid and in a convenient portable On-the-Go inhaler format.”
FDA said the mixture has never been reviewed as safe and effective and the company is violating drug safety regulations.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More